GenomeFrontier’s founder and Chief Scientific Officer, Dr. Sareina Wu, was recently interviewed by BioSpace for an article regarding non-viral vectors’ impact on CAR-T cell therapy.
2021-04-26
She spoke about GenomeFrontier’s latest technology breakthroughs, including the advancement of CAR-T cell therapy using qCART™, a virus-free Quantum Engine™, for development and production of multiplex CAR-T cell therapy.